Article Per Year (5 Year)
p-Index From 2021 - 2026
0.702
P-Index
This Author published in this journals
All Journal Journal of Global Pharma Technology
Panwar, Mangal Singh
Unknown Affiliation
Medicine & Pharmacology

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search
Journal : Journal of Global Pharma Technology

 1 
AN OVERVIEW ON DOSAGE FORM: SUPPOSITORY Jain, Anvesh; Panwar, Mangal Singh
Journal of Global Pharma Technology Volume 17 Issue 01 (2025) Jan 2025
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

In this article we converse about various aspects of suppositories such as their introduction, formulations and therapeutic applications. Suppositories are those type of dosage forms that used to provide medication via the vaginal and rectal routes. Before the invention of suppository, liquid enema was used. Enema’s has a big disadvantage that it leaks out of the cavity where it is inserted. Therefore an alternate method of medication was needed and thus suppository was invented. Suppositories can be described as semi-solid dosage form to provide medications via rectal, vaginal routes where they will melt or dissolve and deliver localized or systemic action. Suppositories are preferred over other dosage form because it comes in different shapes and sizes. Suppositories are one of the very convenient modes for drug delivery. In this article we discuss the fundamental components of suppositories including suppository bases, along with the methods of preparation of suppository. This article also targets to fabricate descriptive information about the advancement of suppositories such as, Bi-layered Suppositories, Hollow Suppositories, Effervescent suppositories, etc. Keywords: Suppositories, Types of Bases, Methods of Preparation, Advancement in suppositories.
BIOLOGICALS AND BIOSIMILAR: ADVANCING HEALTHCARE THROUGH INNOVATION AND ACCESSIBILITY Pal, Pradeep; Chorasiya, Anjali; Jawani, Akanshag; Rathore, Chalsy; Panwar, Mangal Singh
Journal of Global Pharma Technology Volume 17 Issue 02 (2025) Feb. 2025
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

“Biologics” considered one of the fastest growing sectors of the pharmaceutical industry; “Biologics” have introduced many new treatments for life-threatening and rare diseases. The first generation of bio pharmaceutical products produced using recombinant technologies was launched in the 1980s and is now on the way to patent expiration. As a result, research and generic pharmaceutical companies are seizing the opportunity to develop “generic” substitutes for original biologics, referred to here as biosimilars. However, the process of introducing an innovator's biosimilar product is much more complex than the relatively straightforward process of introducing a generic equivalent of an innovator's product based on a new chemical entity. Biologics are produced by cells in culture or whole organisms, which are inherently more variable than chemical synthesis methods. Therefore, unlike generic drugs, it is not possible to create an identical or identical copy of the innovator product. In this way, biosimilars are "similar but not the same" or in other words biosimilars are "a twin but not a clone" of the original biologic innovator product. The field of biosimilars therefore presents several important challenges, including i) validation of similarity, ii) interchangeability of biosimilar and innovative products, iii) possible need for a unique nomenclature to distinguish different bio pharmaceutical products, iv) regulatory framework, v) business opportunities as well as guidance for assistance to manufacturers in product development, vi) intellectual property rights and vii) public safety. Keywords: Biosimilars, Biological drugs, Innovative product, Pharmacovigilance.
AN OVERVIEW ON DOSAGE FORM: SUPPOSITORY Jain, Anvesh; Panwar, Mangal Singh
Journal of Global Pharma Technology Volume 17 Issue 01 (2025) Jan 2025
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

In this article we converse about various aspects of suppositories such as their introduction, formulations and therapeutic applications. Suppositories are those type of dosage forms that used to provide medication via the vaginal and rectal routes. Before the invention of suppository, liquid enema was used. Enema’s has a big disadvantage that it leaks out of the cavity where it is inserted. Therefore an alternate method of medication was needed and thus suppository was invented. Suppositories can be described as semi-solid dosage form to provide medications via rectal, vaginal routes where they will melt or dissolve and deliver localized or systemic action. Suppositories are preferred over other dosage form because it comes in different shapes and sizes. Suppositories are one of the very convenient modes for drug delivery. In this article we discuss the fundamental components of suppositories including suppository bases, along with the methods of preparation of suppository. This article also targets to fabricate descriptive information about the advancement of suppositories such as, Bi-layered Suppositories, Hollow Suppositories, Effervescent suppositories, etc. Keywords: Suppositories, Types of Bases, Methods of Preparation, Advancement in suppositories.
BIOLOGICALS AND BIOSIMILAR: ADVANCING HEALTHCARE THROUGH INNOVATION AND ACCESSIBILITY Pal, Pradeep; Chorasiya, Anjali; Jawani, Akanshag; Rathore, Chalsy; Panwar, Mangal Singh
Journal of Global Pharma Technology Volume 17 Issue 02 (2025) Feb. 2025
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

“Biologics” considered one of the fastest growing sectors of the pharmaceutical industry; “Biologics” have introduced many new treatments for life-threatening and rare diseases. The first generation of bio pharmaceutical products produced using recombinant technologies was launched in the 1980s and is now on the way to patent expiration. As a result, research and generic pharmaceutical companies are seizing the opportunity to develop “generic” substitutes for original biologics, referred to here as biosimilars. However, the process of introducing an innovator's biosimilar product is much more complex than the relatively straightforward process of introducing a generic equivalent of an innovator's product based on a new chemical entity. Biologics are produced by cells in culture or whole organisms, which are inherently more variable than chemical synthesis methods. Therefore, unlike generic drugs, it is not possible to create an identical or identical copy of the innovator product. In this way, biosimilars are "similar but not the same" or in other words biosimilars are "a twin but not a clone" of the original biologic innovator product. The field of biosimilars therefore presents several important challenges, including i) validation of similarity, ii) interchangeability of biosimilar and innovative products, iii) possible need for a unique nomenclature to distinguish different bio pharmaceutical products, iv) regulatory framework, v) business opportunities as well as guidance for assistance to manufacturers in product development, vi) intellectual property rights and vii) public safety. Keywords: Biosimilars, Biological drugs, Innovative product, Pharmacovigilance.
Co-Authors Chorasiya, Anjali Jain, Anvesh Jawani, Akanshag Pal, Pradeep Rathore, Chalsy